The TruSight Oncology Comprehensive test has been approved by the FDA as a companion diagnostic for NTRK-fusion positive solid tumors and RET-fusion positive non–small cell lung cancer.
The FDA has granted approval of the TSO Comprehensive test and its first 2 companion diagnostic (CDx) cancer indications.1 This approval makes it the first comprehensive genomic profiling in vitro diagnostic kit with pancancer claims to receive FDA clearance.
Now, this test is indicated to identify adult and pediatric patients with solid tumors that harbor NTRK gene fusions. These patients may be eligible for treatment with the targeted therapy larotrectinib (Vitrakvi). This agent has shown promising results in clinical trials for patients with NTRK-fusion positive cancers.
The TSO test is also approved to identify adult patients with locally advanced or metastatic NSCLC that harbor RET gene fusions. These patients may be eligible for treatment with selpercatinib (Retevmo), another targeted therapy that is specifically designed for patients with RET fusions or mutations.
"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina, in a press release. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."
The TSO test is a next-generation sequencing-based assay that provides comprehensive genomic profiling of solid tumors. The test interrogates over 500 genes, including genes that are commonly associated with cancer driver mutations, fusions, and copy number variations. Additionally, the test can be utilized to identify biomarkers that may be relevant for targeted therapy, immunotherapy, or clinical trial enrollment.2
By providing a more complete picture of a patient’s tumor biology, the TSO test can help to increase the likelihood of identifying targeted therapy options or clinical trial opportunities.
Five-Year Data Shows CheckMate 9LA Regimen Maintains Survival in NSCLC
September 24th 2024During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
Read More